What is Sonavex?
Sonavex is a specialized medical technology firm focused on the development of automated 3D ultrasound solutions designed to optimize dialysis access management. By integrating real-time monitoring and visualization capabilities through its core product suite—including EchoMark, EchoSure, and EchoMap—the company provides clinical teams with the precision required for fistula maturation and cannulation guidance. This technological approach not only enhances patient outcomes but also delivers measurable economic value to health systems by reducing complications and improving procedural efficiency. Sonavex operates at the intersection of diagnostic imaging and clinical workflow optimization, positioning itself as an essential partner for nephrology and vascular access teams.
How much funding has Sonavex raised?
Sonavex has raised a total of $12.4M across 7 funding rounds:
Angel/Seed
$1M
Private Equity
$2.2M
Series A
$2.2M
Grant
$750K
Unspecified
$3M
Debt
$150K
Stock/Share Issuance
$3.1M
Angel/Seed (2015): $1M, investors not publicly disclosed
Private Equity (2016): $2.2M, investors not publicly disclosed
Series A (2017): $2.2M supported by Tedco, CRCM Venture Capital, the Abell Foundation, and Grey Sky Venture Partners
Grant (2017): $750K featuring National Science Foundation
Unspecified (2019): $3M backed by Texas Medical Center
Debt (2020): $150K with participation from PPP
Stock/Share Issuance (2026): $3.1M, investors not publicly disclosed
Key Investors in Sonavex
Tedco
TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland.
CRCM Venture Capital
CRCM L.P. is a registered investment adviser based in San Francisco, operating since 2012. The firm provides investment advisory services to clients, focusing on tailored financial strategies.
Grey Sky Venture Partners
GSVP specializes in providing comprehensive tools for planning and executing large-scale cruise events, catering to clients organizing corporate retreats, weddings, and other group celebrations at sea.
What's next for Sonavex?
With the successful completion of this major strategic investment, Sonavex is well-positioned to accelerate its commercial expansion and deepen its research and development efforts. The company is expected to focus on broadening the clinical application of its ultrasound platform, potentially targeting new therapeutic areas that require high-fidelity, real-time blood flow monitoring. As Sonavex transitions into this next phase of enterprise-level growth, the focus will likely shift toward scaling its sales infrastructure and strengthening its footprint in both domestic and international healthcare markets. The strategic deployment of these funds will be critical in maintaining the company's competitive edge in the rapidly evolving medical imaging sector.
See full Sonavex company page
